3Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probioticmixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol,2005,100 : 1539 -1546.
4Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1 ) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut ,2005,54:242-249.
5Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update) : American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol,2004, 99:1371-1385.
6Pullan RD, Rhodes J, Ganesh S,et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med,1994,330:811-815.
7Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis, 2004, 10:286- 299.
8Guarner C, Runyon BA, Young S,et al. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol, 1997,26 : 1372-1378.
9Fiocchi C. Microbial factors in the pathogenesis of IBD. Bioscience Microflora,2003 ,22 :5-14.
10Marteau P, Lepage P, Mangin I, et al. gut flora and inflammatory bowel disease. Aliment Phannacol Ther,2004,20( Suppl 4) : 18- 23.
2Kao J,Kwok K,Das KM. Inducing and maintaining remission in ulcerative cofitis: role of high-dose,extended-release mesalamine. J Clin Gastroenterol,2010,44(8): 531-535.
3Lichtenstein GR,Gordon GL,Zakko S,et al. Clinical trial: once- daily mesalamine granules for maintenance of remission ofulcerative colitis - a 6-month placebo-controlled trial. Aliment Pharmacol Ther,2010,32(8): 990-999.
4Oliveira L,Cohen RD. Maintaining remission in ulcerative colitis- -role of once daily extended-release mesalamine. Drug Des Devel Ther,2011,5(6): 111-116.
